Teva and Barr - Top 10 deals of 2008

FierceBiotech's top 10 deals of 2008 featuring Teva's acquistion of Barr Pharmaceuticals.Who: Teva
With: Barr
What: $7.46B

Summary: Teva and Barr's July cash-and-stock deal combined the world's largest and fourth-largest generics makers into one powerhouse. Teva gained Barr's strength in Central Europe and in fast-growing Eastern-European markets. In addition, the buyout expanded Teva's branded drug business. Barr has first-to-market rights for several new generics over the next few years, and it has a strong set of branded women's health treatments. The deal will help Teva achieve its strategic plan to reach $20 billion in sales with a 20 percent margin by 2012.

Teva and Barr - Top 10 deals of 2008

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.